Neo-Probe sets up Israeli company
This article was originally published in Clinica
Neo-Probe (US) has invested $3.2 million in a company in Israel to develop its radio-immunoguided (RIGS) technology. In the first stage of the project the company will manufacture the intraoperative cancer detection system, which uses monoclonal antibodies from Dow Chemical, to identify colon cancer. The system will then be adapted for lung and breast cancer detection.